Nextgen has started preclinical studies of the efficacy of a gene therapy drug for the treatment of androgenic alopecia. It is the expansion of indications for the use of the world's first genotherapeutic drug Neovasculgen with the mechanism of action therapeutic angiogenesis (therapeutic vascular growth).